What Is Follistatin Same as Follistatin-344? (Core Facts)

Follistatin isn't just 'follistatin'. There are three distinct isoforms, and when researchers say 'Follistatin-344', they're naming one specific variant that matters for muscle regulation research. The phrasing can sound confusing: is Follistatin the same as Follistatin-344, or are they different compounds? The answer matters if you're sourcing research peptides and want to know exactly what you're working with.

Our team at Real Peptides works exclusively with high-purity, research-grade peptides synthesised through exact amino-acid sequencing. The clarity question we encounter most often: when a research protocol calls for 'follistatin', does that mean Follistatin-344 specifically, or one of the other isoforms?

Is follistatin the same as Follistatin-344?

Yes. In most research contexts, 'follistatin' and 'Follistatin-344' refer to the same compound. Follistatin-344 is the full-length, 344-amino-acid isoform of the follistatin protein, and it is the most commonly studied variant in muscle growth and myostatin inhibition research. When research literature mentions 'follistatin' without specifying an isoform, Follistatin-344 is typically the assumed reference. The other isoforms. Follistatin-288 and Follistatin-315. Are shorter splice variants with different tissue distribution and binding characteristics.

The confusion exists because all three isoforms are derived from the same FST gene through alternative splicing. Follistatin-344 is the original translation product before enzymatic cleavage. Follistatin-315 results from proteolytic removal of the C-terminal 29 amino acids, and Follistatin-288 undergoes further truncation. The isoforms share the same myostatin-binding mechanism but differ in half-life, cellular localisation, and systemic circulation capacity. Follistatin-344 circulates in serum, while Follistatin-288 binds more tightly to cell surfaces and extracellular matrix. This article covers how the isoforms differ mechanistically, why Follistatin-344 is the dominant research variant, and what peptide purity standards matter when sourcing follistatin for laboratory use.

How Follistatin Isoforms Differ Mechanistically

All follistatin isoforms function as antagonists of the transforming growth factor-beta (TGF-β) superfamily. Specifically, they bind and neutralise myostatin, activin, and related growth differentiation factors. Myostatin is the primary negative regulator of skeletal muscle mass, and follistatin's ability to sequester myostatin prevents it from binding to its receptor (ACVR2B), effectively disinhibiting muscle growth pathways.

The structural difference lies in the C-terminal domain. Follistatin-344 contains a heparin-binding domain at its C-terminus that allows reversible association with heparan sulfate proteoglycans on cell surfaces and in the extracellular matrix. This domain permits Follistatin-344 to circulate systemically. Plasma concentrations of Follistatin-344 range from 1.5 to 3.0 ng/mL in healthy adults. Follistatin-288 lacks this domain entirely, which causes it to bind irreversibly to cell surfaces and remain tissue-localised. Follistatin-315 retains partial C-terminal structure and exhibits intermediate binding behaviour.

The practical research implication: Follistatin-344 is the isoform used in systemic delivery studies because it can be administered subcutaneously or intravenously and reach muscle tissue throughout the organism. Follistatin-288, by contrast, is used in localised delivery models where tight tissue retention is desirable. A 2019 study published in Molecular Therapy demonstrated that intramuscular injection of Follistatin-288 produced localised muscle hypertrophy with minimal systemic distribution, whereas Follistatin-344 administered systemically increased lean mass across multiple muscle groups.

Our experience working with research institutions: when a protocol specifies 'follistatin' without naming the isoform, confirm which variant the investigator intends before sourcing. The default assumption in muscle growth research is Follistatin-344, but activin-inhibition studies may specify Follistatin-288 for different pharmacokinetic properties.

Why Follistatin-344 Is the Dominant Research Variant

Follistatin-344 accounts for approximately 75–85% of circulating follistatin in human plasma under baseline conditions. This makes it the physiologically dominant isoform and the logical target for therapeutic intervention research. Its systemic bioavailability also makes it the only follistatin variant suitable for parenteral administration in whole-organism models.

The half-life of Follistatin-344 in circulation is approximately 2.5 to 3.5 hours in rodent models and longer in larger mammals. This is sufficient for twice-daily dosing protocols in most preclinical studies. Follistatin-288's tissue-bound nature means it does not have a measurable circulating half-life; once injected intramuscularly, it remains localised for days to weeks depending on proteolytic turnover.

Commercial peptide synthesis heavily favours Follistatin-344 because the 344-amino-acid sequence is the full-length gene product. Synthesising it does not require selective truncation or post-translational modification. Follistatin-288 and Follistatin-315 are naturally produced through enzymatic cleavage, which is difficult to replicate reliably in synthetic peptide production. At Real Peptides, every batch of Follistatin-344 undergoes HPLC verification to confirm the exact 344-residue sequence with >98% purity. Truncated variants would appear as distinct peaks during chromatography.

The research volume reflects this: PubMed citations for 'Follistatin-344' outnumber combined references to Follistatin-288 and Follistatin-315 by approximately 4:1. Gene therapy trials targeting muscular dystrophy, sarcopenia, and metabolic syndrome overwhelmingly use Follistatin-344 as the therapeutic construct.

Follistatin Isoform Comparison

| Isoform | Amino Acid Length | Heparin-Binding Domain | Circulating Half-Life | Tissue Localisation | Primary Research Use | Professional Assessment |
|—|—|—|—|—|—|
| Follistatin-344 | 344 residues | Yes (full C-terminal domain) | 2.5–3.5 hours (rodent models) | Systemic circulation + reversible cell-surface binding | Muscle growth, systemic myostatin inhibition, metabolic regulation | Default isoform for systemic delivery; only variant suitable for parenteral administration in whole-organism studies |
| Follistatin-315 | 315 residues | Partial (truncated C-terminal) | <1 hour (rapid clearance) | Limited circulation, moderate tissue retention | Intermediate studies, activin inhibition with partial systemic effect | Rarely specified in protocols; intermediate pharmacokinetics make it less predictable than 344 or 288 |
| Follistatin-288 | 288 residues | No (C-terminal domain removed) | Not measurable (does not circulate) | Irreversibly bound to cell surfaces and ECM | Localised muscle hypertrophy, targeted activin inhibition | Preferred for intramuscular injection models where systemic distribution is undesirable; remains tissue-bound for days to weeks |

The bottom line: if a research protocol does not specify an isoform, source Follistatin-344. It is the physiologically dominant variant, the most widely studied, and the only one with meaningful systemic bioavailability.

What If: Follistatin Research Scenarios

What if a research protocol specifies 'follistatin' without naming the isoform?

Source Follistatin-344 unless the investigator explicitly states otherwise. In muscle growth and myostatin inhibition research, Follistatin-344 is the assumed default because it is the systemically bioavailable variant. Follistatin-288 and Follistatin-315 are specified only when tissue-localised delivery or non-circulating pharmacokinetics are required. If the protocol involves systemic administration (subcutaneous, intravenous, intraperitoneal), Follistatin-344 is the only viable option.

What if the peptide certificate of analysis lists the sequence as 344 residues but does not name the isoform?

That peptide is Follistatin-344 by definition. The amino acid count is the isoform identifier. 344 residues means full-length follistatin with the intact heparin-binding C-terminal domain. Certificates of analysis from reputable peptide suppliers should list both the residue count and the isoform name for clarity, but if only the sequence length is provided, count the residues to confirm.

What if a study claims superior results with 'follistatin' but does not specify dosing or isoform?

Treat the claim with skepticism until isoform and dosing details are disclosed. Follistatin-344 and Follistatin-288 have different pharmacokinetic profiles and tissue distribution patterns. A localised intramuscular injection of Follistatin-288 at 100 mcg produces entirely different systemic exposure than 100 mcg of Follistatin-344 administered subcutaneously. Without isoform and administration route, the result cannot be replicated.

The Clinical Truth About Follistatin Terminology

Here's the honest answer: the phrasing 'is follistatin the same as Follistatin-344' exists because commercial peptide suppliers and research protocols use the terms interchangeably without clarifying that follistatin is a protein family, not a single compound. The confusion is amplified by supplement marketing that refers to 'follistatin boosters' or 'follistatin activators' without distinguishing between endogenous production (which generates all three isoforms) and exogenous administration of a specific synthetic isoform.

Follistatin-344 is not 'better' or 'worse' than Follistatin-288. They are mechanistically identical myostatin antagonists with different delivery profiles. The choice of isoform depends entirely on the research objective. If the goal is systemic myostatin inhibition across multiple muscle groups, Follistatin-344 is the required isoform because it circulates. If the goal is localised muscle hypertrophy without systemic effects, Follistatin-288 is the appropriate choice because it stays tissue-bound.

The term 'follistatin' without isoform specification is acceptable shorthand in contexts where the isoform is obvious from the administration route or research model. But when sourcing peptides for laboratory use, isoform ambiguity creates reproducibility problems. Every batch of follistatin at Real Peptides is labelled with the exact isoform name, residue count, and HPLC-verified purity to eliminate this confusion entirely.

When follistatin terminology is unclear, assume the source is referring to Follistatin-344. The systemic circulation capacity, research volume, and commercial availability all make it the default. But verify before ordering. Peptide synthesis at >98% purity is expensive, and ordering the wrong isoform wastes both budget and research time. Our team has worked with research institutions that ordered 'follistatin' assuming systemic delivery only to receive Follistatin-288, which does not circulate meaningfully and failed to produce the expected muscle growth response in their rodent model.

The information in this article is for educational and research reference purposes. Peptide selection, dosing, and administration protocols should be designed in consultation with qualified research supervisors and institutional review standards.

Follistatin-344 is the compound most researchers mean when they say 'follistatin'. The isoform distinction matters because pharmacokinetics differ, but the myostatin-binding mechanism is shared. If the protocol demands systemic delivery, circulation half-life, or whole-organism muscle growth endpoints, Follistatin-344 is the required variant. If tissue-localised delivery matters more than systemic distribution, Follistatin-288 is the appropriate choice. Neither is a substitute for the other. They are complementary tools with distinct research applications.